Interestingly, its inhibition using the LSD1 scaffolding inhibitor (OG86) increased the binding of H3K4 methyltransferase MLL4 (an enzymatic subunit of COMPASS complex) to the promoter of BAX and activated its expression in leukemic cells, suggesting that LSD1/NuRD complex and COMPASS complex might directly compete for binding to the promoters of differentiation-related genes and tumor suppressors [31]. The gene discussed is BAX; the disease is neoplasm.